Brain metabolism in Alzheimer's dementia: studies of 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects

Nybäck, H; Nyman, H; Blomqvist, G; Sjögren, I; Stone-Elander, S
August 1991
Journal of Neurology, Neurosurgery & Psychiatry;Aug1991, Vol. 54 Issue 8, p672
Academic Journal
journal article
No abstract available.


Related Articles

  • Cerebrospinal fluid pH and monoamine and glucolytic metabolites in Alzheimer's disease. Gottfries, C. G.; Kjällquist, A.; Pontén, U.; Roos, B. E.; Sundbärg, G.; Kjällquist, A; Pontén, U; Sundbärg, G // British Journal of Psychiatry;Mar74, Vol. 124, p280 

    The article discusses the cerebrospinal fluid and monoamine and glucolytic metabolites in Alzheimer's disease. Determinations of acid monoamine metabolites in cerebrospinal fluid (CSF) give valid information on the metabolism of the corresponding amines in the brain tissue. The monoamine...

  • Dexamethasone suppression test and serum prolactin in dementia disorders. Balldin, Jan; Gottfries, Carl-Gerhard; Karlsson, Ingvar; Lindstedt, Göran; Långström, Göran; Wålinder, Jan; Balldin, J; Gottfries, C G; Karlsson, I; Lindstedt, G; Långström, G; Wålinder, J // British Journal of Psychiatry;Sep83, Vol. 143, p277 

    The dexamethasone suppression test (DST) was performed on 21 patients with dementia of the Alzheimer type (DAT), 11 patients with multi-infarct dementia (MI) and 14 healthy controls. Twelve of the DAT patients and eight of the MI patients showed abnormal lack of suppression, compared with just...

  • Cerebrospinal Fluid pH and Monoamine and Glucolytic Metabolites in Alzheimer's Disease. Pontén, Urban // British Journal of Psychiatry;Sep73, Vol. 123 Issue 574, p360 

    An abstract of the research "Cerebrospinal Fluid pH and Monoamine and Glucolytic Metabolites in Alzheimer's Disease," is presented. This study supports the previous observations that the dopamine and 5-hydroxytryptamine metabolism is disturbed in patients with Alzheimer's disease. Furthermore,...

  • Brain Imaging: Aging and Dementia. Cutler, Neal R.; Duara, Ranjan; Creasey, Helen; Grady, Cheryl L.; Haxby, James V.; Schapiro, Mark B.; Rapoport, Stanley // Annals of Internal Medicine;Sep84, Vol. 101 Issue 3, p355 

    Presents information on a study that examined overall brain function and anatomy in healthy men at different ages, patients with presumptive Alzheimer's disease and adults with Down's syndrome. Cerebral metabolism during normal aging; Computed tomographic scanning in normal aging;...

  • Cognitive and neurochemical alterations in hyperhomocysteinemic rat. Gao, Lin; Zeng, Xiao-Ning; Guo, Hong-Ming; Wu, Xu-Ming; Chen, Hui-Juan; Di, Rong-Ke; Wu, Ying // Neurological Sciences;Feb2012, Vol. 33 Issue 1, p39 

    Accumulating data have shown that the level of serum homocysteine in patients with mild cognitive impairment, vascular dementia and Alzheimer's disease is higher than normal while the underlying mechanism is not fully understood. Here, a hyperhomocysteinemic rat model was made by maintaining...

  • Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease. Mattsson, Niklas; Insel, Philip; Tosun, Duygu; Zhang, Jing; Jack Jr, Clifford R.; Galasko, Douglas; Weiner, Michael // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Background:Cerebrospinal fluid (CSF) α-synuclein is reduced in synucleinopathies, including dementia with Lewy bodies, and some studies have found increased CSF α-synuclein in Alzheimer’s disease (AD). No study has explored effects of CSF α-synuclein on brain atrophy. Here we...

  • Kynurenine and its metabolites in Alzheimer's disease patients. Gulaj, E.; Pawlak, K.; Bien, B.; Pawlak, D. // Advances in Medical Sciences (De Gruyter Open);2010, Vol. 55 Issue 2, p204 

    Purpose: The kynurenine pathway (KP) is a major route of tryptophan metabolism. Several metabolites of this pathway are proposed to be involved in the pathogenesis of Alzheimer's disease. The aim of this study was to evaluate peripheral KP in patients with Alzheimer type dementia and a detailed...

  • Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Selnes, Per; Blennow, Kaj; Zetterberg, Henrik; Grambaite, Ramune; Rosengren, Lars; Johnsen, Lisbeth; Stenset, Vidar; Fladby, Tormod // Cerebrospinal Fluid Research;2010, Vol. 7, p10 

    Background: Alzheimer's disease (AD) and cerebrovascular disease (CVD) including chronic small vessel disease of the brain (SVD) are the most frequent causes of dementia. AD is associated with metabolism of amyloid precursor protein (APP) and low levels of amyloid-b peptide (Ab) X-42 in the...

  • Metabolic correlates of executive dysfunction. Bracco, L.; Bessi, V.; Piccini, C.; Mosconi, L.; Pupi, A.; Sorbi, S. // Journal of Neurology;Aug2007, Vol. 254 Issue 8, p1052 

    This study was designed to examine the correlations between resting-state brain glucose metabolism (CMRglc), as measured with Positron Emission Tomography and performance on executive function tasks in Alzheimer's disease (AD), while taking into account the severity of cognitive deterioration....

  • Insulin may play a role in the treatment of Alzheimer's disease. Craft, Suzanne // American Family Physician;8/1/1995, Vol. 52 Issue 2, p603 

    Suggests that insulin may play an important role in improving memory function in patient's with Alzheimer's disease. Study consisting of 22 patients with mild Alzheimer's disease and 13 healthy patients; Evaluation of effects of three metabolic states; Administration of neuropsychologic tests...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics